$CELG Company News Bull rolls on, but opportun
Post# of 102254
Posted On: 07/14/2014 10:40:40 AM
$CELG Company News
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Celgene shareholders approve 2-for-1 stock split 8:51 a.m. June 19, 2014 - Ciara Linnane
Celgene drops 1.9%, among worst S&P 500 losers 9:32 a.m. May 29, 2014 - Sue Chang
Higher rates are coming — here’s how you prepare 8:38 a.m. May 12, 2014 - Jeff Reeves
Wall Street up for second day on earnings cheer; biotechs rebound: Stock market live blog recap 4:03 p.m. April 29, 2014 - blogs.marketwatch.com
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
What ‘Game of Thrones’ can teach you about money 8:30 a.m. April 5, 2014 - Wallace Witkowski
Biotechs, bonds and more from the 'tempest in a microsecond' 8:32 a.m. April 2, 2014 - Shawn Langlois
Play-it-safe stock investors may take some risk on jobs 8:31 a.m. March 30, 2014 - Wallace Witkowski
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
3 Biotech Stocks That Belong in Your Portfolio 4:45 a.m. Today - InvestorPlace.com
A Contrarian's Take 2:07 a.m. July 12, 2014 - Barrons.com
Oncolytics Up on Patient Enrolment Completion - Analyst Blog 3:00 p.m. July 11, 2014 - Zacks.com
Buying The Dip - The Game Plan 11:41 a.m. July 10, 2014 - Seeking Alpha
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog 11:30 a.m. July 10, 2014 - Zacks.com
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) 6:27 a.m. July 10, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM 6:00 a.m. July 10, 2014 - TheStreet.com
'Fast Money' Recap: Digging Into Oil Prices 5:00 a.m. July 10, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains 7:53 p.m. July 9, 2014 - TheStreet.com
Pluristem Initiates Trial in South Korea - Analyst Blog 6:00 p.m. July 9, 2014 - Zacks.com
3 Drugs Stocks Driving The Industry Higher 1:03 p.m. July 9, 2014 - TheStreet.com
Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback 11:37 a.m. July 9, 2014 - benzinga.com
Celgene Drug Otezla Fails Trial, But Street Sanguine 10:52 a.m. July 9, 2014 - Investors Business Daily
Celgene Slips; Drug Candidate Fails Phase III Trial Endpoint 8:37 a.m. July 9, 2014 - benzinga.com
Celgene's Phase 3 Study of Arthritis Drug Misses Target 7:51 a.m. July 9, 2014 - The Wall Street Journal Interactive Edition
UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings 7:49 a.m. July 9, 2014 - 247WallSt.com
Otezla fails to hit primary endpoint in Phase 3 label expansion trial 7:28 a.m. July 9, 2014 - Seeking Alpha
AbbVie Raises Offer for Shire 7:22 p.m. July 8, 2014 - The Wall Street Journal Interactive Edition
Alexion Pharma Looks To Life Beyond Its Blockbuster 1:42 p.m. July 8, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: BMY, CAT, CELG 12:29 p.m. July 8, 2014 - TheStreet.com
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis 7:00 a.m. July 9, 2014 - BusinessWire - BZX
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma 6:40 a.m. July 9, 2014 - PR Newswire - PRF
Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific 5:40 a.m. July 8, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014 8:31 a.m. July 1, 2014 - BusinessWire - BZX
CORRECTING and REPLACINGCelgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 2:28 p.m. June 26, 2014 - BusinessWire - BZX
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before 9:37 a.m. June 26, 2014 - ACCESSWIRE
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 8:30 a.m. June 26, 2014 - BusinessWire - BZX
Celgene Stockholders Approve Two-for-One Stock Split 8:30 a.m. June 19, 2014 - BusinessWire - BZX
Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA 8:58 a.m. June 14, 2014 - BusinessWire - BZX
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia 3:00 a.m. June 14, 2014 - BusinessWire - BZX
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST®) Trial Presented at EHA Annual Congress 5:44 p.m. June 13, 2014 - BusinessWire - BZX
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver 9:31 a.m. June 11, 2014 - PR Newswire - PRF
Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma 7:50 a.m. June 6, 2014 - PR Newswire - PRF
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014 9:01 a.m. June 1, 2014 - BusinessWire - BZX
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics 9:53 a.m. May 29, 2014 - ACCESSWIRE
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
Organizational Changes Strengthen and Expand Celgene Leadership Team 6:00 a.m. May 22, 2014 - BusinessWire - BZX
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth 8:41 a.m. May 21, 2014 - PR Newswire - PRF
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Celgene shareholders approve 2-for-1 stock split 8:51 a.m. June 19, 2014 - Ciara Linnane
Celgene drops 1.9%, among worst S&P 500 losers 9:32 a.m. May 29, 2014 - Sue Chang
Higher rates are coming — here’s how you prepare 8:38 a.m. May 12, 2014 - Jeff Reeves
Wall Street up for second day on earnings cheer; biotechs rebound: Stock market live blog recap 4:03 p.m. April 29, 2014 - blogs.marketwatch.com
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Sue Chang
What ‘Game of Thrones’ can teach you about money 8:30 a.m. April 5, 2014 - Wallace Witkowski
Biotechs, bonds and more from the 'tempest in a microsecond' 8:32 a.m. April 2, 2014 - Shawn Langlois
Play-it-safe stock investors may take some risk on jobs 8:31 a.m. March 30, 2014 - Wallace Witkowski
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
44 stocks on takeover target radar: Morgan Stanley 12:48 p.m. March 25, 2014 - blogs.marketwatch.com
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
3 Biotech Stocks That Belong in Your Portfolio 4:45 a.m. Today - InvestorPlace.com
A Contrarian's Take 2:07 a.m. July 12, 2014 - Barrons.com
Oncolytics Up on Patient Enrolment Completion - Analyst Blog 3:00 p.m. July 11, 2014 - Zacks.com
Buying The Dip - The Game Plan 11:41 a.m. July 10, 2014 - Seeking Alpha
Celgene's Otezla Disappoints in Ankylosing Spondylitis Study - Analyst Blog 11:30 a.m. July 10, 2014 - Zacks.com
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) 6:27 a.m. July 10, 2014 - Seeking Alpha
Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM 6:00 a.m. July 10, 2014 - TheStreet.com
'Fast Money' Recap: Digging Into Oil Prices 5:00 a.m. July 10, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains 7:53 p.m. July 9, 2014 - TheStreet.com
Pluristem Initiates Trial in South Korea - Analyst Blog 6:00 p.m. July 9, 2014 - Zacks.com
3 Drugs Stocks Driving The Industry Higher 1:03 p.m. July 9, 2014 - TheStreet.com
Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback 11:37 a.m. July 9, 2014 - benzinga.com
Celgene Drug Otezla Fails Trial, But Street Sanguine 10:52 a.m. July 9, 2014 - Investors Business Daily
Celgene Slips; Drug Candidate Fails Phase III Trial Endpoint 8:37 a.m. July 9, 2014 - benzinga.com
Celgene's Phase 3 Study of Arthritis Drug Misses Target 7:51 a.m. July 9, 2014 - The Wall Street Journal Interactive Edition
UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings 7:49 a.m. July 9, 2014 - 247WallSt.com
Otezla fails to hit primary endpoint in Phase 3 label expansion trial 7:28 a.m. July 9, 2014 - Seeking Alpha
AbbVie Raises Offer for Shire 7:22 p.m. July 8, 2014 - The Wall Street Journal Interactive Edition
Alexion Pharma Looks To Life Beyond Its Blockbuster 1:42 p.m. July 8, 2014 - Investors Business Daily
3 Stocks Reiterated As A Buy: BMY, CAT, CELG 12:29 p.m. July 8, 2014 - TheStreet.com
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis 7:00 a.m. July 9, 2014 - BusinessWire - BZX
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma 6:40 a.m. July 9, 2014 - PR Newswire - PRF
Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific 5:40 a.m. July 8, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014 8:31 a.m. July 1, 2014 - BusinessWire - BZX
CORRECTING and REPLACINGCelgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 2:28 p.m. June 26, 2014 - BusinessWire - BZX
Companies Chasing Gold Nugget of Immuno-Oncology Like Never Before 9:37 a.m. June 26, 2014 - ACCESSWIRE
Celgene Corporation Mourns the Passing of Board of Director Member, Rodman L. Drake 8:30 a.m. June 26, 2014 - BusinessWire - BZX
Celgene Stockholders Approve Two-for-One Stock Split 8:30 a.m. June 19, 2014 - BusinessWire - BZX
Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA 8:58 a.m. June 14, 2014 - BusinessWire - BZX
Studies Presented at 19th European Hematology Association Annual Congress Evaluate Activin Receptor Ligand Trap Programs in Beta-Thalassemia 3:00 a.m. June 14, 2014 - BusinessWire - BZX
Analysis of Health-Related Quality of Life Measures from the MM-020/IFM 07-01 (FIRST®) Trial Presented at EHA Annual Congress 5:44 p.m. June 13, 2014 - BusinessWire - BZX
Critical Alerts For JC Penney, Brown Forman, Schlumberger, Celgene, and DirecTV Technology Released By InvestorsObserver 9:31 a.m. June 11, 2014 - PR Newswire - PRF
Oral OTEZLA® (Apremilast) Showed Long-Term Clinical Benefits in Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Oral OTEZLA® (Apremilast) Monotherapy Showed Long-Term Clinical Benefits in DMARD-Naïve Patients with Active Psoriatic Arthritis 7:30 a.m. June 11, 2014 - BusinessWire - BZX
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma 7:50 a.m. June 6, 2014 - PR Newswire - PRF
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014 9:01 a.m. June 1, 2014 - BusinessWire - BZX
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics 9:53 a.m. May 29, 2014 - ACCESSWIRE
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK 5:50 a.m. May 29, 2014 - PR Newswire - PRF
Organizational Changes Strengthen and Expand Celgene Leadership Team 6:00 a.m. May 22, 2014 - BusinessWire - BZX
Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth 8:41 a.m. May 21, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼